Presentation Scheduled for 11:35am EDT
ALISO VIEJO, Calif., June 3 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Ron Andrews, CEO and Vice Chairman, is scheduled to make an investor presentation at Noble Financial's 5th Annual Equity Conference at 11:35am EDT on Tuesday, June 9, 2009. The conference will be held at the Seminole Hard Rock Hotel and Casino in Hollywood, Florida on June 8-9, 2009.
A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.
About Clarient
Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary 'companion' diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com
Press Contact:
Kristy DelMuto
Gregory FCA
(610) 228-2118
kristy@gregoryfca.com
Investor Contact:
Matt Clawson
Allen & Caron Inc
(949) 474-4300
matt@allencaron.com
SOURCE Clarient, Inc.